Dako and Quintiles announced this week that they would work together to develop personalized medicine products, with the first of their projects focused on supporting AstraZeneca's development of an oncology drug.

As part of the non-exclusive alliance, "Dako and Quintiles will offer integrated drug-diagnostic development services and companion diagnostic products," the companies said in a statement. "The first such collaboration will support AstraZeneca in the development of one of its leading oncology compounds."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.